ICON Public (NASDAQ:ICLR) Earns Outperform Rating from William Blair

ICON Public (NASDAQ:ICLR)‘s stock had its “outperform” rating reiterated by investment analysts at William Blair in a research note issued to investors on Tuesday,Benzinga reports.

Other analysts also recently issued reports about the company. Robert W. Baird lowered their price objective on ICON Public from $249.00 to $225.00 and set a “neutral” rating for the company in a research note on Wednesday, November 20th. Redburn Atlantic assumed coverage on ICON Public in a research note on Monday, October 14th. They set a “neutral” rating and a $311.00 price objective on the stock. Baird R W lowered shares of ICON Public from a “strong-buy” rating to a “hold” rating in a research note on Thursday, October 24th. Leerink Partnrs upgraded shares of ICON Public to a “strong-buy” rating in a report on Wednesday, September 18th. Finally, Truist Financial restated a “buy” rating and set a $284.00 price target (down from $295.00) on shares of ICON Public in a report on Wednesday, December 18th. Four equities research analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $287.00.

ICON Public Price Performance

Shares of ICLR opened at $199.47 on Tuesday. The stock has a market cap of $16.46 billion, a P/E ratio of 22.24, a P/E/G ratio of 1.54 and a beta of 1.20. The business’s fifty day moving average is $210.79 and its 200 day moving average is $270.01. The company has a quick ratio of 1.34, a current ratio of 1.34 and a debt-to-equity ratio of 0.35. ICON Public has a 12-month low of $183.38 and a 12-month high of $347.72.

ICON Public (NASDAQ:ICLR) last issued its quarterly earnings data on Wednesday, October 23rd. The medical research company reported $3.35 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analyst estimates of $2.13 billion. ICON Public had a net margin of 9.00% and a return on equity of 11.91%. The firm’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the prior year, the business earned $3.10 earnings per share. Sell-side analysts anticipate that ICON Public will post 13.42 earnings per share for the current fiscal year.

Institutional Investors Weigh In On ICON Public

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Foyston Gordon & Payne Inc bought a new position in ICON Public during the third quarter worth about $11,672,000. Icon Wealth Advisors LLC boosted its holdings in ICON Public by 861.1% in the 3rd quarter. Icon Wealth Advisors LLC now owns 13,215 shares of the medical research company’s stock worth $3,797,000 after buying an additional 11,840 shares during the period. Whittier Trust Co. grew its stake in ICON Public by 12.3% in the 3rd quarter. Whittier Trust Co. now owns 4,020 shares of the medical research company’s stock valued at $1,155,000 after buying an additional 441 shares in the last quarter. Sara Bay Financial purchased a new position in ICON Public in the 3rd quarter valued at approximately $1,143,000. Finally, Steph & Co. raised its holdings in ICON Public by 3.7% during the 4th quarter. Steph & Co. now owns 1,560 shares of the medical research company’s stock valued at $327,000 after acquiring an additional 55 shares during the period. 95.61% of the stock is currently owned by institutional investors.

About ICON Public

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.